Related Experiment Video
Updated: Aug 5, 2026
05:59
High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Published on: October 20, 2023
Recommendations on Switching or Deprescribing Hypnotic Medications for Insomnia
Deutsches Arzteblatt International
|July 31, 2026
Summary
Discontinuing hypnotic medications requires a drug-specific tapering strategy, especially for long-term use or dependence. Gradual dose reduction is key, with behavioral therapy as a recommended adjunct for managing insomnia treatment withdrawal.
Area of Science:
- Pharmacology
- Sleep Medicine
- Evidence-Based Medicine
Background:
- Insomnia affects 10-30% of the global population, with significant hypnotic medication dependence.
- Current recommendations for switching or discontinuing hypnotics are incomplete, necessitating updated guidance.
- Regional variations in care and drug classes require tailored, evidence-based recommendations.
Purpose of the Study:
- To develop practical, evidence-based recommendations for switching and discontinuing hypnotic medications.
- To supplement existing insomnia treatment guidelines with drug-specific protocols.
- To address the complexity of hypnotic drug switching and dependence management.
Main Methods:
- A comprehensive narrative review of publications from 1953 to 2026.
- Inclusion of diverse study types: guidelines, meta-analyses, systematic reviews, RCTs, and observational studies.
- Development of new recommendations via a consensus process, including a consensus conference and Delphi method.
Main Results:
- Abrupt discontinuation is feasible for short-term use or drugs without withdrawal symptoms (e.g., daridorexant, melatonin).
- Gradual tapering (10-25% weekly reduction) is recommended for benzodiazepine receptor agonists, antidepressants, antipsychotics, and gabapentinoids after >2 weeks of use.
- Longer tapers are advised for high-dose or long-term use (≥1 year); behavioral therapy improves outcomes (RR: 1.68).
Conclusions:
- A drug-specific, evidence-based approach is crucial for safely switching or discontinuing hypnotic medications.
- Protocols should consider drug class, dose, duration of use, and patient-specific factors.
- Integrating non-pharmacological treatments like behavioral therapy enhances treatment discontinuation success.
Related Concept Videos
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:14CNS Depressants: Barbiturates and Benzodiazepines
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
01:23Sedatives and Hypnotics: Overview
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:20Sedatives and Hypnotics Drugs: Barbiturates
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...